Background
==========

Quinine (QN) remains a first-line drug for the treatment of severe malaria that is still used as a second-line therapy for uncomplicated malaria in many countries \[[@B1]\]. Despite the efficacy of QN against chloroquine-resistant *Plasmodium falciparum*isolates, reports of QN resistance (QNR) have been increasing. In the 1980s, the frequency of clinical failures increased in Southeast Asia and Africa \[[@B2]-[@B4]\]. The mechanism of QNR is complex, multigenic, and not well understood. QNR has been associated with mutations in both the *P. falciparum*multidrug resistance gene *mdr1*(*Pfmdr1*) \[[@B5]\] and the chloroquine resistance transporter gene *Pfcrt*\[[@B6]\]. Other genetic polymorphisms, such as mutations in the resistance protein gene *Pfmrp*\[[@B7]\] and variations of microsatellite length in the sodium/hydrogen exchanger gene *Pfnhe-1*\[[@B8]\], may contribute to QNR. Using quantitative trait loci (QTL) on the genetic cross of HB3 and Dd2 strains, Ferdig *et al*identified genes on chromosome 5, encoding *Pfmdr1*, on chromosome 7, encoding *Pfcrt*and on chromosome 13, encoding *Pfnhe-1*, which were associated with QN reduced susceptibility \[[@B8]\]. Sequences of Pfnhe-1 showed multiple and complex variations such as point polymorphisms at three separate codons (790, 894 and 950) and as microsatellite variations in three different repeat sequences (msR1, ms3580 and ms4760). However, the three point polymorphisms and microsatellite polymorphisms msR1 and ms3580 showed no significant association with QN susceptibility. The investigations of the microsatellite ms4760 polymorphisms in culture-adapted isolates from around the world showed that an increased number of the amino acid motif DNNND was associated with a decreased QN susceptibility, and that an increased number of NHNDNHNNDDD motifs was associated with an increased QN susceptibility \[[@B8],[@B9]\]. The association of two repeats with a high QN inhibitory concentration of 50% (IC~50~) was found in a case of QN clinical failure in a traveller from Senegal \[[@B10]\]. In contrast, a recent multivariate analysis performed on 83 freshly collected clinical isolates from Madagascar and 13 African countries did not find an association between QN susceptibility and *Pfnhe-1*microsatellite polymorphisms \[[@B11]\]. A similar absence of association was observed in 91 isolates from various countries on different continents (Pelleau S. *et al*. submitted). Given that the influence of *Pfnhe*on QN susceptibility has been shown to be strain-dependent, these apparently conflicting results may be explained, in part, by differences in the geographic origin of the parasites analysed, as their local selection history and genetic background varies.

Thus, further epidemiological investigation is required to determine the context in which *Pfnhe*can be used as a molecular marker of QNR. In this work, ms4760 polymorphism was analized and its association tested with *in vitro*susceptibility to QN in African isolates from a single geographical region, Pointe-Noire in the Republic of Congo.

Methods
=======

Reference culture-adapted strains and clinical isolates of *Plasmodium falciparum*
----------------------------------------------------------------------------------

Between March 2005 and January 2006, 74 *P. falciparum*clinical isolates were collected from patients with uncomplicated malaria at the Medical Service of Total Exploration et Production, Pointe-Noire (Republic of Congo) \[[@B12]\]. Two cloned strains of *P. falciparum*were used for quality control (3D7 Africa and W2 Indochina). These clones were obtained from MR4-ATCC (Manassas, VA, USA). They were maintained in culture in RPMI 1640 (Invitrogen, Paisley, UK) that was supplemented with 10% human serum (Abcys S.A. Paris, France) and buffered with 25 mM HEPES and 25 mM NaHCO~3~. The parasites were grown in type A+ human blood under controlled atmospheric conditions (10% O~2~, 5% CO~2~, and 85% N~2~) at 37°C with a humidity of 95%. They were synchronized twice with sorbitol before use \[[@B13]\]. Clonality was verified using PCR genotyping of the polymorphic genetic markers, *msp1*and *msp2*, and the microsatellite loci \[[@B14],[@B15]\].

*In vitro*assay
---------------

The QN was purchased from Sigma (Saint Louis, MO, USA). The QN was first dissolved in methanol and then diluted in water to obtain final concentrations ranging from 5 to 3200 nM.

For the *in vitro*isotopic microtest, 200 μl of the suspension of synchronous parasitized red blood cells (final parasitaemia, 0.5%; final haematocrit, 1.5%) per well were plated in 96-well plates that contained serial QN concentrations. Parasite growth was assessed by adding 1 μCi of tritiated hypoxanthine with a specific activity of 14.1 Ci/mmol (Perkin-Elmer, Courtaboeuf, France) to each well at time zero. The plates were then incubated for 48 h under controlled atmospheric conditions. Immediately after incubation, the plates were frozen and then thawed to lyse the erythrocytes. The contents of each well were collected on standard filter microplates (Unifilter GF/B; Perkin-Elmer) and washed using a cell harvester (Filter-Mate Cell Harvester; Perkin-Elmer). The filter microplates were dried and 25 μl of a scintillation cocktail (Microscint O; Perkin-Elmer) was added to each well. The radioactivity incorporated by the parasites was then measured using a scintillation counter (Top Count; Perkin-Elmer). The drug concentration that could inhibit 50% of the parasite growth (IC~50~) was calculated assuming that it corresponded to the drug concentration at which the incorporation of tritiated hypoxanthine by the parasite was 50% of that incorporated in the drug-free, control wells. IC~50~values were determined using a non-linear regression analysis of log-based dose-response curves (Riasmart, Packard, Meriden, USA).

Genotyping of the *Pfnhe*ms4760 microsatellite polymorphisms
------------------------------------------------------------

Parasite DNA from 100 μl of infected blood was extracted using the E.Z.N.A. Blood DNA kit (Omega Bio-Tek, GA, USA). A sequence containing the previously described ms4760 microsatellite \[[@B8]\] was amplified using the *pfnhe*-3802F 5\'-TTATTAAATGAATATAAAGA-3\' and *pfnhe*-4322R 5\'-TTTTTTATCATTACTAAAGA-3\' primers. Sequencing was performed using ABI Prism Big Dye Terminator v1.1 Cycle Sequencing Ready Reaction Kits (Applied Biosystems, CA, USA), as directed by the manufacturer. Sequences were analysed with BioEdit sequence alignment editor (version 7.0.9.0) software.

Statistical analysis
--------------------

Data were analysed using R software (version 2.10.1) and GraphPad Prism (version 5.01). Differences between the median QN IC~50~values of isolates harbouring one, two or three DNNND repeats were tested using the Kruskal-Wallis test. The median QN IC~50~values of isolates with one or two NHNDNHNNDDD repeats were compared using the Mann Whitney test.

Results
=======

The mean QN IC~50~of the 74 isolates was 381.9 nM, CI95% \[330.7-433.1\] (min-max: 36-1097 nM). Four isolates (5.4%) had a QN IC~50~\> 800 nM (Table [1](#T1){ref-type="table"}) that corresponds to the *in vitro*QNR threshold. Twenty-seven different *Pfnhe-1*genotypes were observed among the 74 isolates, and eighteen were identified as new genotypes (GenBank accession numbers [FJ392810](FJ392810) to [FJ392827](FJ392827)). The DNNND repeats varied from 1 to 3. There was no statistically significant association (p = 0.84) between the median QN IC~50~value and the number of DNNND repeats (medians at 335, 316 and 330 nM, for isolates harbouring one, two or three repeats, respectively) (Figure [1](#F1){ref-type="fig"}). No statistically significant association was observed (p = 0.92) between the median QN IC~50~value of isolates and the number of NHNDNHNNDDD repeats (medians at 328 and 329 nM, for isolates with one and two repeats, respectively).

###### 

*In vitro*susceptibility and *Pfnhe*-1 polymorphisms of the 74 *Plasmodium falciparum*isolates from the Republic of Congo

  ------------------------------------------------------------------------------------------------------------------
  Isolates   Cpm\           Cpm\               QN IC~50~   No DNNND repeat   No NHNDNHNNDDD\   No genotype profile
             without drug   With highest QN\                                 repeat            
                            concentration                                                      
  ---------- -------------- ------------------ ----------- ----------------- ----------------- ---------------------
  16517      23404          1440               1097        3                 2                 ms4760-27

  16612      49650          8273               888         1                 2                 ms4760-3

  16520      6512           1077               882         1                 2                 ms4760-3

  16094      2007           620                862         2                 1                 ms4760-24

  16980      2151           980                782         2                 2                 ms4760-33

  17267      2558           455                776         2                 2                 ms4760-1

  16631      1807           282                750         1                 2                 ms4760-3

  16698      1263           353                740         2                 1                 ms4760-6

  16960      2011           714                689         2                 2                 ms4760-1

  16958      19732          861                645         3                 2                 ms4760-30

  16983      3710           943                627         3                 2                 ms4760-1

  16957      19773          1300               615         1                 2                 ms4760-29

  16966      2264           545                604         2                 2                 ms4760-31

  16941      18540          1175               576         1                 2                 ms4760-3

  16991      2804           815                567         1                 1                 ms4760-36

  16953      5675           1249               564         1                 2                 ms4760-12

  16539      44532          4112               537         1                 2                 ms4760-3

  17250      6558           606                506         1                 2                 ms4760-3

  16942      10927          1163               502         1                 2                 ms4760-3

  16959      9886           914                488         2                 2                 ms4760-1

  17008      2151           961                482         1                 2                 ms4760-35

  16986      2302           624                481         2                 2                 ms4760-1

  16968      8477           962                457         2                 2                 ms4760-1

  17249      1276           412                408         1                 2                 ms4760-22

  17216      3179           539                404         1                 2                 ms4760-38

  17253      9717           1091               396         2                 1                 ms4760-6

  16987      7232           938                388         3                 1                 ms4760-15

  16349      28606          2048               377         3                 1                 ms4760-25

  17231      3545           389                354         1                 2                 ms4760-39

  16518      8912           1361               351         3                 1                 ms4760-7

  16955      9379           1188               346         3                 2                 ms4760-27

  17211      6451           655                346         1                 2                 ms4760-3

  16695      27421          2316               341         1                 2                 ms4760-3

  16996      1347           597                340         2                 2                 ms4760-34

  17208      18356          1208               335         1                 2                 ms4760-3

  16536      6617           847                333         2                 2                 ms4760-1

  16365      4631           724                332         1                 2                 ms4760-22

  16979      7449           990                326         2                 2                 ms4760-18

  17202      11053          929                319         1                 2                 ms4760-3

  16364      12210          1990               316         2                 2                 ms4760-26

  16331      8912           1113               314         3                 2                 ms4760-9

  15868      1530           498                309         1                 2                 ms4760-22

  16610      4063           961                305         3                 1                 ms4760-7

  16535      16007          1274               291         3                 1                 ms4760-15

  16323      43074          5859               290         1                 2                 ms4760-12

  16992      9464           1111               276         1                 2                 ms4760-12

  17237      12385          873                269         1                 2                 ms4760-3

  17305      21667          1398               269         2                 2                 ms4760-3

  16305      11269          917                265         1                 2                 ms4760-3

  17303      18553          1646               264         2                 2                 ms4760-1

  17212      2755           520                259         1                 2                 ms4760-3

  16304      16194          738                254         2                 2                 ms4760-1

  17241      5758           447                254         1                 2                 ms4760-3

  16970      2359           705                247         1                 1                 ms4760-32

  16995      7642           1004               247         2                 2                 ms4760-1

  17210      11018          1370               244         1                 2                 ms4760-22

  17233      12100          956                231         2                 1                 ms4760-6

  17265      1593           238                226         2                 2                 ms4760-1

  17214      2421           316                224         2                 2                 ms4760-37

  17209      3499           680                216         3                 2                 ms4760-9

  17007      3633           1159               212         3                 2                 ms4760-9

  16116      11417          999                204         2                 2                 ms4760-18

  17201      25594          2530               204         1                 1                 ms4760-36

  17304      24453          1982               199         2                 2                 ms4760-1

  16086      10918          699                174         3                 1                 ms4760-15

  17283      4391           315                146         3                 2                 ms4760-1

  17010      2897           1103               141         3                 2                 ms4760-9

  16117      17474          1291               121         2                 2                 ms4760-1

  16078      1654           396                106         2                 2                 ms4760-1

  16085      5229           707                86          2                 1                 ms4760-6

  17301      39337          2016               84          1                 2                 ms4760-12

  15867      6893           739                73          1                 2                 ms4760-3

  16091      17320          1695               67          2                 2                 ms4760-1

  16077      4539           353                36          1                 2                 ms4760-23
  ------------------------------------------------------------------------------------------------------------------

Cpm = count per minute

IC~50~= Inhibitory concentration 50% in nM

QN = quinine

*Pfnhe- 1*ms4760 microsatellite genotype profiles according to the GenBank

![**Distribution of quinine (QN) IC~50~versus the repeats number of DNNND or NHNDNHNNDDD**. The horizontal bars indicate median values.](1475-2875-10-37-1){#F1}

Discussion
==========

QN has been used to treat malaria for more than 350 years in Africa, with little emergence and spread of resistance. QN remains the first line anti-malarial drug for the treatment of complicated malaria in Europe and Africa. However, despite the efficacy of QN against chloroquine-resistant strains, the emergence of QN resistance has been observed. The first cases of QN clinical failure were observed in Brazil and Asia in the 1960s; then in the 1980s, clinical failures became more frequent in Southeast Asia, South America and Africa. However, QN resistance is not yet a significant problem in Africa, and QN remains the first-line drug to treat severe malaria and a second-line therapy for uncomplicated malaria in some areas of Africa.

Although some reports of QN treatment failure exist, it is difficult to confirm QN resistance because of the short elimination half-life of the drug, the requirement to administer it three times a day for at least five days, drug intolerance that often leads to poor compliance and a lack of reliable data on the correlation between QN IC~50~and clinical failure. Maximizing the efficacy and longevity of QN as a tool for the control of malaria will depend critically on the pursuit of intensive research toward the identification of *in vitro*markers of QNR and the implementation of *in vitro*and *in vivo*surveillance programs, such as those championed by the Worldwide Antimalarial Resistance Network \[[@B16],[@B17]\]. Specifically, there is a need to identify molecular markers that effectively predict QN resistance and enable the active surveillance of temporal trends in parasite susceptibility \[[@B18]\]. The present study aimed to test the association between the *Pfnhe*polymorphism and QN susceptibility in clinical isolates from Pointe-Noire in Congo to assess the validity of *Pfnhe*as a molecular marker of QN susceptibility in this region.

The level of susceptibility to QN remained high, with a mean QN IC~50~of 382 nM and with 4/74 isolates (5.4%) that exceed the QNR threshold of 800 nM \[[@B19]\]. The threshold at which QN *in vitro*susceptibility is considered to be compromised is arbitrary, and different studies have set the following thresholds: 300 nM \[[@B20]\], 500 nM \[[@B21]\] or 800 nM. If a QNR threshold of 500 nM is applied here, 19/74 isolates exceed this value. These results suggest that QN treatment is still effective against the chloroquine-resistant parasites that are found in this area, where the prevalence of chloroquine-resistant parasites has reached 75% \[[@B12]\].

A high level of *Pfnhe-1*microsatellite sequence polymorphisms was found (27 genotypes for 74 isolates). Previous studies reported from 8 genotypes for 71 isolates \[[@B8]\] to 35 for 60 isolates \[[@B22]\]. DNNND and NHNDNHNNDDD repeat numbers ranged from 1 to 3 and 1 to 2, respectively. However, neither DNNND nor NHNDNHNNDDD repeat polymorphisms were linked to QN susceptibility.

According to this study and previous studies, the association between QN *in vitro*susceptibility and the *Pfnhe-1*microsatellite genotype appears to be geographically dependent.

One explanation for this could be variation in genetic background. A specific genetic background observed in Asia may allow the observed contribution of *Pfnhe*polymorphism on QN *in vitro*susceptibility. This explanation is consistent with: i) the first evidence of *Pfnhe*-QNR association from QTL analysis using Americano-Asian cross strains \[[@B8]\], ii) that most associations identified have been shown among Asian strains \[[@B8],[@B9],[@B22]\] and iii) that at least 5 genes spanning the *P. falciparum*genome influence the QNR *in vitro*phenotype with an additive effect or with pairwise interactions \[[@B8]\].

Additionally, these genetic dissimilarities between African and Asian plasmodial populations may be accentuated by different local selection histories. The best-documented genomic modifications by a local selection process relate to drug pressure. Several studies have shown that drug pressure may involve extended linkage disequilibrium around a drug resistance associated gene \[[@B23]\]. This is characterized by a strong genetic diversity loss, called a selective sweep. This process stretch may be modified by: i) drug use and ii) malaria transmission level. A reduced drug use and higher malaria transmission level in Africa would be consistent with the lower selective sweep and an absence of linkage disequilibrium between *Pfnhe*and other cooperative drug response genes or selected compensatory mutations. For example, QTL analysis on chromosome 13 located 60 genes of unknown function as being close to *Pfnhe*\[[@B8]\]. They would be more or less linked depending on drug pressure and malaria transmission level if QN pressure selects at least one of them. In Kenya there is an association between two DNNND repeats in the ms4760 *Pfnhe*microsatellite and a reduced susceptibility to quinine in 29 *P. falciparum*isolates \[[@B24]\]. This is consistent with the historic precedent of the spread of drug resistance around the world. The emergence of chloroquine resistance in Asia was followed by an initial introduction into East Africa and spreading across the African continent. Geographic proximity may explain plasmodial population migration. Moreover, East African plasmodial populations may exhibit genetic dissimilarities to other African populations \[[@B14]\].

As the QN response is controlled by multiple genes with complex interactions, one can expect: i) higher sensitivity to genetic background than if the response was controlled by only one gene, ii) higher sensitivity to parameters that may cause linkage disequilibrium between genes and iii) various combinations of gene polymorphisms may result in similar QNR phenotypes.

Conclusions
===========

In summary, although studies have demonstrated that *Pfnhe-1*contributes to QNR \[[@B24]\], the present study and another recent study \[[@B11]\] did not show an association between *Pfnhe-1*polymorphism and QNR. Currently, *Pfnhe-1*cannot be used as a QNR molecular marker when evaluating field isolates, especially in Africa in the context of a low level of quinine selection pressure. Further studies, using more parasite samples from South East Asia with reduced susceptibility to QN, are required to confirm or reject the use of the *Pfnhe-1*gene as a QNR marker in this geographic region.
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